Could a pill reach and fight aggressive brain tumors? early trial hints at possibility
NCT ID NCT05076513
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests the drug niraparib (Zejula) in people with two types of brain cancer: newly diagnosed glioblastoma and recurrent glioma with specific genetic changes (IDH mutation and ATRX loss). The study first checks if the drug reaches the tumor tissue, then gives it to those who show a response, combined with radiation or alone. Up to 42 participants will be enrolled to see if niraparib can slow tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Niraparib (Zejula), a cancer drug taken as a pill
What this could lead to
If successful, this could point toward a new treatment option for aggressive brain cancers like glioblastoma and certain recurrent gliomas.
What could go wrong
This is a very early (Phase 0) trial with only 42 participants, so it is too soon to know if niraparib will be effective or safe for these brain cancers. The drug may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States